Influence of oral contraceptives on circulation immune response. I. Effect of combination type contraceptives. 1974

K N Rangnekar, and S S Rao, and U M Joshi

UI MeSH Term Description Entries
D007110 Immunity, Active Resistance to a disease agent resulting from the production of specific antibodies by the host, either after exposure to the disease or after vaccination. Active Immune Response,Active Immune Responses,Active Immunities,Active Immunity,Immune Response, Active,Immune Responses, Active,Immunities, Active,Response, Active Immune,Responses, Active Immune
D007112 Immunity, Maternally-Acquired Resistance to a disease-causing agent induced by the introduction of maternal immunity into the fetus by transplacental transfer or into the neonate through colostrum and milk. Fetal Immunity, Maternally-Acquired,Maternally-Acquired Immunity,Neonatal Immunity, Maternally-Acquired,Immunity, Maternally Acquired,Fetal Immunities, Maternally-Acquired,Fetal Immunity, Maternally Acquired,Immunity, Maternally-Acquired Fetal,Immunity, Maternally-Acquired Neonatal,Maternally Acquired Immunities,Maternally Acquired Immunity,Maternally-Acquired Fetal Immunities,Maternally-Acquired Fetal Immunity,Maternally-Acquired Immunities,Maternally-Acquired Neonatal Immunities,Maternally-Acquired Neonatal Immunity,Neonatal Immunities, Maternally-Acquired,Neonatal Immunity, Maternally Acquired
D008656 Mestranol The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-,Ethinyl Estradiol 3-Methyl Ether,Ethinyl Estradiol 3 Methyl Ether
D009641 Norethynodrel A synthetic progestational hormone with actions and uses similar to those of PROGESTERONE. It has been used in the treatment of functional uterine bleeding and ENDOMETRIOSIS. As a contraceptive (CONTRACEPTIVE AGENTS), it has usually been administered in combination with MESTRANOL. 19-Norpregn-5(10)-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Norethynodrel, (8 alpha)-(+-)-Isomer
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D003280 Contraceptives, Oral, Synthetic Oral contraceptives which owe their effectiveness to synthetic preparations.
D004338 Drug Combinations Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. Drug Combination,Combination, Drug,Combinations, Drug
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females

Related Publications

K N Rangnekar, and S S Rao, and U M Joshi
June 1979, Journal of obstetrics and gynaecology of India,
K N Rangnekar, and S S Rao, and U M Joshi
October 1990, American family physician,
K N Rangnekar, and S S Rao, and U M Joshi
June 1984, Contraception,
K N Rangnekar, and S S Rao, and U M Joshi
January 1994, Current therapy in endocrinology and metabolism,
K N Rangnekar, and S S Rao, and U M Joshi
January 1997, Current therapy in endocrinology and metabolism,
K N Rangnekar, and S S Rao, and U M Joshi
January 1984, Clinical pharmacy,
K N Rangnekar, and S S Rao, and U M Joshi
August 1983, Journal of obstetrics and gynaecology of India,
K N Rangnekar, and S S Rao, and U M Joshi
January 1995, European journal of clinical pharmacology,
K N Rangnekar, and S S Rao, and U M Joshi
December 1990, American journal of obstetrics and gynecology,
K N Rangnekar, and S S Rao, and U M Joshi
June 1977, Cancer,
Copied contents to your clipboard!